ARTICLE | Discovery & Translation
Science Spotlight: Moving KRAS inhibitors upstream to high-risk patients
Plus: engineered receptors to target low-CD70 solid tumors, Xaira’s virtual cell model, and infectious disease company innovations
March 18, 2026 9:35 PM UTC
A study in Science suggests KRAS inhibitors could move upstream from treating late-stage pancreatic cancer to preventing it in high-risk patients.
The University of Pennsylvania team gave oral KRAS-targeted drugs to engineered mice that develop precancerous changes in the pancreas before advancing to full-blown cancer. A 28-day course of treatment followed by intermittent dosing (1 week on/1 week off) with oral RAS(ON) inhibitors from Revolution Medicines Inc. (NASDAQ:RVMD) wiped out much of the microscopic precursor disease, pushed back tumor onset by months, and extended survival. ...